Drugs & Aging

, Volume 22, Issue 6, pp 471–482

Adenosine A2A Receptor Antagonists for Parkinson’s Disease

Rationale, Therapeutic Potential and Clinical Experience
Leading Article

Abstract

Long-term disability in Parkinson’s disease (PD) is related to progression of the underlying disease and the emergence of complications of chronic levodopa therapy. There is a need for new medications that can slow the underlying progression of degeneration, improve PD symptoms in early disease without inducing dyskinesia, and improve motor fluctuations and ‘off’ time in advanced disease without worsening dyskinesia. Much interest has focused on the development of nondopaminergic therapies, with antagonists of the adenosine A2A receptor emerging as leading candidates. A2A receptors are selectively expressed in the basal ganglia and specific A2A antagonists reverse motor deficits without causing dyskinesia in animal models of PD. The antiparkinsonian potential of A2A receptor blockade has been expanded further by convergent epidemiological and laboratory findings suggesting a possible neuroprotective effect of A2A receptor antagonists in PD. Istradefylline (KW-6002) is the first of several adenosine A2A receptor antagonists in development for PD to advance to phase III clinical trials. Initial studies indicate that in patients with motor fluctuations on levodopa, addition of istradefylline reduces ‘off’ time. Additional studies are necessary to evaluate the benefit of istradefylline as monotherapy in early disease, its effect on the development of dyskinesia, and its effect on disease progression.

References

  1. 1.
    Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448–58PubMedCrossRefGoogle Scholar
  2. 2.
    Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484–91PubMedCrossRefGoogle Scholar
  3. 3.
    Kase H, Richardson P, Jenner P, editors. Adenosine receptors and Parkinson’s disease. San Diego (CA): Academic Press, 2000Google Scholar
  4. 4.
    Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson’s disease. Pharmacol Ther 2005; 105: 267–310PubMedCrossRefGoogle Scholar
  5. 5.
    Cunha RA. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem Int 2002; 38: 107–25CrossRefGoogle Scholar
  6. 6.
    Tohyama M, Takatsuji K. Atlas of neuroactive substances and their receptors in the rat. Oxford: Oxford University Press, 1998Google Scholar
  7. 7.
    Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A2A receptor antagonist treatment of Parkinson’s disease. Neurology 2003; 61: 293–6PubMedCrossRefGoogle Scholar
  8. 8.
    Hauser RA, Hubble JP, Truong DD, et al. Randomized trial of the adenosine A2A antagonist istradefylline in advanced PD. Neurology 2003; 61: 297–303PubMedCrossRefGoogle Scholar
  9. 9.
    Stacy MA, the US-005 and US-006 Investigator Group. Istradefylline (KW-6002) as adjunctive therapy in patients with advanced Parkinson’s disease: a positive safety profile with supporting efficacy [abstract]. Mov Disord 2004; 19Suppl. 9: S215–S6Google Scholar
  10. 10.
    Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366–75PubMedCrossRefGoogle Scholar
  11. 11.
    Kase H, Aoyama S, Ichimura M, et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease. Neurology 2003; 61 (11 Suppl. 6): S97–S100PubMedCrossRefGoogle Scholar
  12. 12.
    Wichmann T, DeLong MR. Functional neuroanatomy of the basal ganglia in Parkinson’s disease. Adv Neurol 2003; 91: 9–18PubMedGoogle Scholar
  13. 13.
    Fink JS, Weaver DR, Rivkees SA, et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 1992; 14: 186–95PubMedCrossRefGoogle Scholar
  14. 14.
    Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991; 57: 1062–7PubMedCrossRefGoogle Scholar
  15. 15.
    Ochi M, Koga K, Kurokawa M, et al. Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000; 100: 53–62PubMedCrossRefGoogle Scholar
  16. 16.
    Bastia E, Xu Y-H, Scibelli AC, et al. A crucial role for forebrain adenosine A2A receptors in amphetamine sensitization. Neuropsychopharmacology 2005 May; 30(5): 891–900PubMedCrossRefGoogle Scholar
  17. 17.
    Pinna A, Di Chiara G, Wardas J, et al. Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopaminedenervated rats. Eur J Neurosci 1996; 8: 1176–81PubMedCrossRefGoogle Scholar
  18. 18.
    Fenu S, Pinna A, Ongini E, et al. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 1997; 321: 143–7PubMedCrossRefGoogle Scholar
  19. 19.
    Koga K, Kurokawa M, Ochi M, et al. Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 2000; 408: 249–55PubMedCrossRefGoogle Scholar
  20. 20.
    Stromberg I, Popoli P, Muller CE, et al. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur J Neurosci 2000; 12: 4033–7PubMedCrossRefGoogle Scholar
  21. 21.
    Pinna A, Fenu S, Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopaminelesioned rats. Synapse 2001; 39: 233–8CrossRefGoogle Scholar
  22. 22.
    Kanda T, Shiozaki S, Shimada J, et al. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 1994; 256: 263–8PubMedCrossRefGoogle Scholar
  23. 23.
    Hauber W, Nagel J, Sauer R, et al. Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen. Neuroreport 1998; 9: 1803–6PubMedCrossRefGoogle Scholar
  24. 24.
    Shiozaki S, Ichikawa S, Nakamura J, et al. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999; 147: 90–5PubMedCrossRefGoogle Scholar
  25. 25.
    Wardas J, Konieczny J, Lorenc-Koci E. SCH 58261, an A2A adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 2001; 41: 160–71PubMedCrossRefGoogle Scholar
  26. 26.
    Correa M, Wisniecki A, Betz A, et al. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 2004; 148: 47–54PubMedCrossRefGoogle Scholar
  27. 27.
    Simola N, Fenu S, Baraldi PG, et al. Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 2004; 189: 182–8PubMedCrossRefGoogle Scholar
  28. 28.
    Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998; 43: 507–13PubMedCrossRefGoogle Scholar
  29. 29.
    Grondin R, Bedard PJ, Hadj Tahar A, et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999; 52: 1673–7PubMedCrossRefGoogle Scholar
  30. 30.
    Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective Dl or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000; 162: 321–7PubMedCrossRefGoogle Scholar
  31. 31.
    Hernan MA, Takkouche B, Caamano-Isorna F, et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 2002; 52: 276–84PubMedCrossRefGoogle Scholar
  32. 32.
    Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283: 2674–9PubMedCrossRefGoogle Scholar
  33. 33.
    Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 2001; 50: 56–63PubMedCrossRefGoogle Scholar
  34. 34.
    Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: a case-control study. Neurology 2000; 55: 1350–8PubMedCrossRefGoogle Scholar
  35. 35.
    Ascherio A, Chen H, Schwarzschild MA, et al. Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology 2003; 60: 790–5PubMedCrossRefGoogle Scholar
  36. 36.
    Ascherio A, Weisskopf MG, O’Reilly EJ. Coffee consumption, gender, and Parkinson’s disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004; 160: 977–84PubMedCrossRefGoogle Scholar
  37. 37.
    Chen J-F, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci 2001; 21: RC143, 1–6PubMedGoogle Scholar
  38. 38.
    Xu K, Xu Y-H, Chen J-F, et al. Caffeine’s neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett 2002; 322: 13–6PubMedCrossRefGoogle Scholar
  39. 39.
    Joghataie MT, Roghani M, Negahdar F, et al. Protective effect of caffeine against neurodegeneration in a model of Parkinson’s disease in rat: behavioral and histochemical evidence. Parkinsonism Relat Disord 2004; 10: 465–8PubMedCrossRefGoogle Scholar
  40. 40.
    Oztas E, Kalda A, Xu K, et al. Caffeine attenuates MPTP-induced loss of dopaminergic neurons in substantia nigra in mice. Program No. 487.6. Washington, DC: Society for Neuroscience, 2002Google Scholar
  41. 41.
    Ikeda K, Kurokawa M, Aoyama S, et al. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson’s disease. J Neurochem 2002; 80: 262–70PubMedCrossRefGoogle Scholar
  42. 42.
    Pierri M, Vaudano E, Sager T, et al. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005 Mar; 48(4): 517–24PubMedCrossRefGoogle Scholar
  43. 43.
    Ledent C, Vaugeois JM, Schiffmann SN, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997; 388: 674–8PubMedCrossRefGoogle Scholar
  44. 44.
    Chen J-F, Huang Z, Ma J, et al. A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999; 19: 9192–200PubMedGoogle Scholar
  45. 45.
    Fredduzzi S, Moratalla R, Monopoli A, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002; 22: 1054–62PubMedGoogle Scholar
  46. 46.
    Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol 2003; 184: 285–94PubMedCrossRefGoogle Scholar
  47. 47.
    Bové J, Marin C, Bonastre M, et al. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 2002; 46: 251–7PubMedCrossRefGoogle Scholar
  48. 48.
    Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J Neurochem 2003; 84: 1398–410PubMedCrossRefGoogle Scholar
  49. 49.
    Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in Parkinson’s disease patients with motor fluctuations and dyskinesia. J Clin Neuropharmacol 2000; 23: 75–81CrossRefGoogle Scholar
  50. 50.
    LeWitt PA, US-005/US-006 Clinical Investigator Group. ‘Off’ time reduction from adjunctive use of istradefylline (KW-6002) in levodopa-treated patients with advanced Parkinson’s disease [abstract]. Mov Disord 2004; 19Suppl. 9: S222Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Departments of Neurology, Pharmacology and Experimental TherapeuticsUniversity of South Florida and Tampa General HealthcareTampaUSA
  2. 2.Department of NeurologyMassachusetts General Hospital and Harvard Medical SchoolBostonUSA
  3. 3.Parkinson’s Disease and Movement Disorders CenterUniversity of South FloridaTampaUSA

Personalised recommendations